Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)
Clinical trial NCT04229836 · COMPLETED
Trial details
- NCT number
- NCT04229836
- Sponsor
- Almirall, S.A.
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-17
- Primary completion
- 2021-11-15
- Enrollment
- 178
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.